VivoSim Labs, Inc.

VIVS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Balance Sheet
Annual Quarterly

Balance Sheet

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Assets
Cash & Equivalents $5.0M $11.3M $2.9M $15.3M $28.7M $37.4M $27.4M $36.5M
Accounts Receivable $32.0K $30.0K $33.0K $152.0K $0 $0 $111.0K $503.0K
Inventory — $0 $297.0K $0 — — $0 $490.0K
Total Current Assets $6.6M $12.1M $3.9M $17.0M $29.5M $38.4M $28.3M $38.6M
Property, Plant & Equipment $206.0K $419.0K $669.0K $902.0K $662.0K $381.0K $0 $1.8M
Goodwill — — — — — — — —
Intangible Assets (Excl. Goodwill) — — — — — — — —
Total Assets $7.4M $14.7M $6.3M $20.3M $33.3M $39.9M $28.4M $40.6M
Liabilities
Accounts Payable $1.0M $1.6M $627.0K $331.0K $415.0K $281.0K $720.0K $628.0K
Total Current Liabilities $2.8M $3.7M $1.9M $3.7M $1.4M $721.0K $1.8M $3.7M
Long-Term Debt — — — — — — — —
Total Liabilities $8.5M $4.2M $2.7M $5.0M $3.1M $721.0K $1.8M $4.3M
Stockholders' Equity
Retained Earnings $-356.0M $-342.2M $-339.7M $-325.0M $-307.7M $-296.3M $-279.5M $-260.8M
Total Stockholders' Equity $-1.1M $10.5M $364.0K $15.3M $30.2M $39.2M $26.6M $36.3M
← Newer Page 1 of 2 Older →